Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 3
2009 2
2010 2
2012 3
2013 7
2014 5
2015 6
2016 8
2017 6
2018 6
2019 16
2020 8
2021 7
2022 9
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 4 Clear Cell Renal Cell Carcinoma"
Page 1
Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis.
Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, Bass EB, Allaf ME. Pierorazio PM, et al. J Urol. 2016 Oct;196(4):989-99. doi: 10.1016/j.juro.2016.04.081. Epub 2016 May 6. J Urol. 2016. PMID: 27157369 Free PMC article. Review.
We summarize evidence on effectiveness and comparative effectiveness of these treatment approaches for patients with a renal mass suspicious for localized renal cell carcinoma. MATERIALS AND METHODS: We searched MEDLINE, Embase and the Cochrane Central …
We summarize evidence on effectiveness and comparative effectiveness of these treatment approaches for patients with a renal mass sus …
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Khoja L, et al. Ann Oncol. 2017 Oct 1;28(10):2377-2385. doi: 10.1093/annonc/mdx286. Ann Oncol. 2017. PMID: 28945858 Free article. Review.
Grade 3/4 irAE were more common with CTLA-4 mAbs compared with PD-1 (31% versus 10%). ...Comparison of irAE from the three most studied tumour types in PD-1 mAbs trials [melanoma (n = 2048), non-small-cell lung cancer (n = 1030) and renal cel …
Grade 3/4 irAE were more common with CTLA-4 mAbs compared with PD-1 (31% versus 10%). ...Comparison of irAE from the th …
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Wu Z, Chen Q, Qu L, Li M, Wang L, Mir MC, Carbonara U, Pandolfo SD, Black PC, Paul AK, Di Lorenzo G, Porpiglia F, Mari A, Necchi A, Rouprêt M, Psutka SP, Autorino R. Wu Z, et al. Eur Urol. 2022 Apr;81(4):414-425. doi: 10.1016/j.eururo.2022.01.028. Epub 2022 Jan 31. Eur Urol. 2022. PMID: 35101302 Free article. Review.
The pooled overall incidence was 81.6% (95% confidence interval [CI] 78.0-84.7) for any-grade trAEs and 29.3% (95% CI 24.9-34.1) for grade 3 trAEs. The pooled overall incidence was 34.3% (95% CI 28.5-40.7) for any-grade irAEs and 10.2% (95%CI 8.2-12.7) for …
The pooled overall incidence was 81.6% (95% confidence interval [CI] 78.0-84.7) for any-grade trAEs and 29.3% (95% CI 24.9-34.1) for …
Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, Fernandes R. Hussaini S, et al. Cancer Treat Rev. 2021 Jan;92:102134. doi: 10.1016/j.ctrv.2020.102134. Epub 2020 Dec 3. Cancer Treat Rev. 2021. PMID: 33302134
RESULTS: Of 3384 unique citations, 51 studies met inclusion criteria. Studies included melanoma (n = 21), lung (n = 19), renal (n = 4), urothelial (n = 1), head and neck (n = 2) and gastrointestinal cancers (n = 1). ...Improved treatment efficacy in patients who dev …
RESULTS: Of 3384 unique citations, 51 studies met inclusion criteria. Studies included melanoma (n = 21), lung (n = 19), renal (n = …
Diagnostic Performance of DWI for Differentiating High- From Low-Grade Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Woo S, et al. AJR Am J Roentgenol. 2017 Dec;209(6):W374-W381. doi: 10.2214/AJR.17.18283. Epub 2017 Oct 12. AJR Am J Roentgenol. 2017. PMID: 29023154 Review.
OBJECTIVE: The purpose of our study was to review the diagnostic performance of DWI for differentiating high- from low-grade clear cell renal cell carcinoma (RCC). MATERIALS AND METHODS: MEDLINE, EMBASE, and Cochrane library databases wer …
OBJECTIVE: The purpose of our study was to review the diagnostic performance of DWI for differentiating high- from low-grade clear …
Neoadjuvant therapy in renal cell carcinoma with tumor thrombus: A systematic review and meta-analysis.
Gu L, Peng C, Li H, Jia T, Chen X, Wang H, Du S, Tang L, Liang Q, Wang B, Ma X, Zhang X. Gu L, et al. Crit Rev Oncol Hematol. 2024 Apr;196:104316. doi: 10.1016/j.critrevonc.2024.104316. Epub 2024 Mar 2. Crit Rev Oncol Hematol. 2024. PMID: 38432444 Review.
To evaluate the efficacy, feasibility and safety of neoadjuvant therapy (NAT) for renal cell carcinoma with tumor thrombus (RCC-TT) in terms of response, perioperative and oncological outcomes, and compare the results between neoadjuvant and non-neoadjuvant g …
To evaluate the efficacy, feasibility and safety of neoadjuvant therapy (NAT) for renal cell carcinoma with tumor throm …
Targeted therapy for metastatic renal cell carcinoma.
Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B. Hofmann F, et al. Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2. Cochrane Database Syst Rev. 2020. PMID: 33058158 Free PMC article.
BACKGROUND: Several comparative randomised controlled trials (RCTs) have been performed including combinations of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors since the publication of a Cochrane Review on targeted therapy for metastatic renal cell …
BACKGROUND: Several comparative randomised controlled trials (RCTs) have been performed including combinations of tyrosine kinase inhibitors …
Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy.
Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K, Canfield SE, Hora M, Kuczyk MA, Merseburger AS, Mulders PFA, Powles T, Staehler M, Ljungberg B, Volpe A. Marconi L, et al. Eur Urol. 2016 Apr;69(4):660-673. doi: 10.1016/j.eururo.2015.07.072. Epub 2015 Aug 29. Eur Urol. 2016. PMID: 26323946 Review.
CONTEXT: The role of percutaneous renal tumour biopsy (RTB) remains controversial due to uncertainties regarding its diagnostic accuracy and safety. ...PATIENT SUMMARY: We systematically reviewed the literature to assess the safety and diagnostic performance of renal …
CONTEXT: The role of percutaneous renal tumour biopsy (RTB) remains controversial due to uncertainties regarding its diagnostic accur …
Network meta-analysis of second-line treatment in metastatic renal cell carcinoma: efficacy and safety.
El Rassy E, Aoun F, Sleilaty G, Kattan J, Banyurwabuke B, Zanaty M, Bakouny Z, Albisinni S, Peltier A, Roumeguere T. El Rassy E, et al. Future Oncol. 2017 Dec;13(29):2709-2717. doi: 10.2217/fon-2017-0268. Epub 2017 Nov 29. Future Oncol. 2017. PMID: 29183164 Review.
This paper aims to compare the approved second-line treatment options in metastatic renal cell carcinoma. A network meta-analysis (NMA) using the frequentist approach and generalized pairwise modeling was computed for the approved drugs in this setting. ...Th …
This paper aims to compare the approved second-line treatment options in metastatic renal cell carcinoma. A network met …
Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis.
Tang X, Liu T, Zang X, Liu H, Wang D, Chen H, Zhang B. Tang X, et al. PLoS One. 2013 May 7;8(5):e62847. doi: 10.1371/journal.pone.0062847. Print 2013. PLoS One. 2013. PMID: 23667530 Free PMC article. Review.
PURPOSE: Metastatic renal cell carcinoma (mRCC), as one of the most immunogenic tumors has been the focus of adoptive cellular immunotherapy (ACI), but the effects of ACI on objective response and survival in patients with mRCC are still controversial. ...Ris …
PURPOSE: Metastatic renal cell carcinoma (mRCC), as one of the most immunogenic tumors has been the focus of adoptive c …
78 results